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Cardiac fibrosis are central to various cardiovascular diseases. Research on the
mechanisms and therapeutic targets for cardiac fibrosis has advanced greatly in recent
years. However, while many anti-fibrotic treatments have been studied in animal models
and seem promising, translation of experimental findings into human patients has been
rather limited. Thus, several potential new treatments which have shown to reduce
cardiac fibrosis in animal models have either not been tested in humans or proved to
be disappointing in clinical trials. A majority of clinical studies are of small size or have
not been maintained for long enough periods. In addition, although some conventional
therapies, such as renin-angiotensin-aldosterone system (RAAS) inhibitors, have been
shown to reduce cardiac fibrosis in humans, cardiac fibrosis persists in patients with
heart failure even when treated with these conventional therapies, indicating a need
to develop novel and effective anti-fibrotic therapies in cardiovascular disease. In this
review article, we summarize anti-fibrotic therapies for cardiovascular disease in humans,
discuss the limitations of currently used therapies, along with possible reasons for
the failure of so many anti-fibrotic drugs at the clinical level. We will then explore the
future directions of anti-fibrotic therapies on cardiovascular disease, and this will include
emerging anti-fibrotics that show promise, such as relaxin. A better understanding of
the differences between animal models and human pathology, and improved insight into
carefully designed trials on appropriate end-points and appropriate dosing need to be
considered to identify more effective anti-fibrotics for treating cardiovascular fibrosis in
human patients.
Keywords: cardiac fibrosis, anti-fibrotic therapies, clinical trials, diffuse fibrosis, cardiac magnetic resonance
imaging, collagen turnover markers, diastolic function
INTRODUCTION
Cardiac fibrosis is a hallmark of various cardiovascular disease such as hypertension, myocardial
infarction (MI), and ischemic, dilated, and hypertrophic cardiomyopathies. Cardiac fibrosis
not only leads to cardiac diastolic dysfunction, but is also a major determinant of malignant
arrhythmias and end-stage systolic heart failure and consequently, increases the risk of cardiac
death. There are two types of fibrosis: regional fibrosis (reparative fibrosis, scarring from MI)
and diffuse fibrosis (reactive fibrosis, interstitial fibrosis in response to different stimuli). Cardiac
fibrosis can be definitively diagnosed by endomyocardial biopsies, but they are an invasive
evaluation only representative in diffuse fibrosis. Circulating biomarkers, particularly collagen
turnover markers, are widely used to noninvasively assess cardiac fibrosis, however they are
not reliable and unable to differentiate regional fibrosis from diffuse fibrosis. Cardiac magnetic
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resonance imaging (CMR) is an emerging technique to accurately
and noninvasively evaluate regional and diffuse cardiac fibrosis
by late gadolinium enhancement and post-contrast myocardial
longitudinal relaxation time (T1) mapping, respectively, but
CMR is expensive and not easily accessible. Functional
consequences of cardiac fibrosis, particularly impaired left
ventricular (LV) relaxation and heart failure, are also potential,
albeit nonspecific, markers of fibrosis.
It is known that a complex interaction involving a network
of growth factors/cytokines/hormones and fibroblasts and other
cell types (such as cardiomyocytes, monocytes, lymphocytes)
is responsible for initiating and maintaining fibrotic response
(Kong et al., 2014). In addition to resident fibroblasts,
fibroblasts originate from circulating pecursors, sometimes
termed fibrocytes (Fang et al., 2013), endothelial cells or epithelial
cells (Kong et al., 2014). Renin-angiotensin-aldosterone system
(RAAS), growth factors [such as transforming growth factor
(TGF)-β], endothelin, matricellular proteins (such as connective
tissue growth factor (CTGF) and proinflammatory factors (such
as tumor necrosis factor (TNF-α), interleukin (IL)-6 and IL-1)
are some of the best studied mediators implicated in cardiac
fibrosis (Kong et al., 2014). Recently, new mediators with
therapeutic potential of cardiac fibrosis have been emerging such
as cardiotrophin-1, galectin, and miRNAs etc. (Fang et al., 2015;
Heymans et al., 2015). Although many anti-fibrotic therapies on
cardiac fibrosis seem promising in experimental models, clinical
data are limited and mixed. Most of new anti-fibrotic therapies
have not been evaluated in patients. Some clinical data have
demonstrated benefits on cardiac fibrosis mainly with RAAS
inhibitors, but most clinical trials on anti-fibrotic drugs are
disappointing. This review will summarize findings from clinical
trials of anti-fibrotic therapies on cardiac fibrosis (Table 1) and
discuss the discrepancy between animal research and clinical
trials as well as future directions.
ANTI-FIBROTIC THERAPIES ON CARDIAC
FIBROSIS IN CLINICAL TRIALS
RAAS Inhibitors
The first family of anti-fibrotic drugs are inhibitors of angiotensin
II. Angiotensin II interacts with angiotensin II type I receptors,
which stimulates fibroblast proliferation, and increases collagen
synthesis (Kong et al., 2014). Several clinical studies have shown
that both angiotensin-converting enzyme (ACE) inhibitors and
angiotensin receptor blockers reduce cardiac fibrosis in patients
independent of their antihypertensive effects. In hypertensive
patients, endomyocardial biopsies at baseline and 6 months
revealed a decrease of collagen volume fraction (CVF) only
in the group treated with lisinopril (n = 18), but not with
hydrochlorothiazide (n = 17) (Brilla et al., 2000). A comparison
between losartan (n = 21) and amlodipine (n = 16) given
for 1 year in hypertensive patients revealed that only losartan
significant decreased both CVF (by endomyocardial biopsies)
and the carboxy-terminal peptide of procollagen type I (PICP)
(López et al., 2001). Another study demonstrated that in patients
with hypertensive heart disease, losartan treatment for 12months
decreased CVF (by endomyocardial biopsies) and LV chamber
stiffness in patients with severe fibrosis (n = 7), but not in
those with nonsevere fibrosis (n = 12) (Díez et al., 2002).
In patients with end-stage renal disease, losartan (n = 13)
more effectively suppressed cardiac fibrosis than did enalapril
(n = 13) or amlodipine (n = 13) (Shibasaki et al., 2005).
Another small study showed attenuation of progression of
cardiac fibrosis with losartan in patients with nonobstructive
hypertrophic cardiomyopathy (Shimada et al., 2013). Treatment
with candesartan for 24 months also reduced the amino-terminal
peptide of type III procollagen (PIIINP) in patients with atrial
fibrillation (Kawamura et al., 2010).
The mineralo-corticoid receptor antagonists, spironolactone
and eplerenone, also have anti-fibrotic effects in humans.
Additional treatment of spironolactone for 6 months improved
LV diastolic function and decreased PICP and PIIINP in 80
patients with metabolic syndrome treated with angiotensin II
inhibition (Kosmala et al., 2011). In another study of 113 patients
with obesity and mild LV diastolic dysfunction, spironolactone
treatment for 6 months improved myocardial deformation and
decreased PICP and PIIINP (Kosmala et al., 2013). In 44 patients
with diastolic heart failure, eplerenone reduced PIIINP at 12
months after treatment, associated with modest improvement
of diastolic function (Mak et al., 2009). Similar findings were
made in another study showing that eplerenone reduced the
amino-terminal peptide of type I procollagen (PINP) and PICP
in 44 patients with heart failure with preserved ejection fraction
(Deswal et al., 2011).
Although the above clinical studies have shown that RAAS
inhibitors reduces cardiac fibrosis in humans, the study
population in these studies is rather small. Furthermore,
inhibition of RAAS only modestly regresses cardiac fibrosis.
Cardiac fibrosis persists in heart failure patients even when
treated as recommended by the official guidelines (Querejeta
et al., 2004). Thus, there is a compelling need to develop novel
and effective anti-fibrotic therapies in cardiovascular disease.
Inflammation Modulators
Inflammatory modulation might have beneficial effects on
cardiac fibrosis and heart failure since inflammation is involved
in the formation and progression of cardiac fibrosis. TNF-α plays
an important role in cardiac fibrosis. However, the RENEWAL
study (Mann et al., 2004) which examined the effect of TNF-α
antagonist etanercept in patients with heart failure was negative.
Additionally, the ATTACH trial was stopped prematurely as
the high dose of the TNF-α antagonist infliximab increased all-
causemortality in patients withmoderate-to-severe chronic heart
failure (Chung et al., 2003). The finding that TNF receptor 1 and
2 exert opposing effects on cardiac remodelingmay partly explain
that direct blockade of one inflammatory actor could cause these
unexpected clinical results (Hamid et al., 2009).
Statins possess potent anti-inflammatory effects and are
widely used in cardiovascular disease. Rosuvastatin attenuated
cardiac fibrosis in animal models (Chang et al., 2009), which
is supported by a small clinical study showing that statin
therapy for 6 months reduced PIIINP in heart failure population
(n = 56) (Abulhul et al., 2012). However, two large-scale clinical
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TABLE 1 | Anti-fibrotic therapies on cardiac fibrosis in clinical trials.






Brilla et al., 2000 Lisinopril 6 months 35 Lisinopril but not hydrochlorothiazide decreased CVF in hypertensive patients.
López et al., 2001 Losartan 12 months 37 Losartan but not amlodipine decreased CVF and PICP in hypertensive patients.
Díez et al., 2002 Losartan 12 months 19 Losartan decreased CVF and LV chamber stiffness in hypertensive patients with
severe fibrosis, but not in those with nonsevere fibrosis.
Shibasaki et al., 2005 Losartan 6 months 39 Losartan more effectively suppressed cardiac fibrosis than enalapril or
amlodipine in patients with end-stage renal disease.
Shimada et al., 2013 Losartan 12 months 20 Losartan attenuated the progression of cardiac fibrosis in patients with
nonobstructive hypertrophic cardiomyopathy.
Kawamura et al., 2010 Candesartan 24 months 153 Candesartan reduced PIIINP in patients with atrial fibrillation.
Kosmala et al., 2011 Spironolactone 6 months 80 Additional spironolactone decreased PICP and PIIINP in patients with metabolic
syndrome.
Kosmala et al., 2013 Spironolactone 6 months 113 Spironolactone improved myocardial deformation and decreased PICP and
PIIINP in patients with obesity and mild LV diastolic dysfunction.
Mak et al., 2009 Eplerenone 12 months 44 Eplerenone reduced PIIINP and modestly improved diastolic function in patients
with diastolic heart failure.
Deswal et al., 2011 Eplerenone 6 months 44 Eplerenone reduced PINP and PICP in patients with heart failure with preserved
ejection fraction.
INFLAMMATION MODULATORS
RENEWAL Etanercept 24 weeks 2,048 The study ruled out a clinically relevant benefit of etanercept on the rate of death
or hospitalization due to chronic heart failure in patients with heart failure.
ATTACH Infliximab At 0, 2, 6
weeks
150 High dose of infliximab increased all-cause mortality in patients with
moderate-severe heart failure.
Abulhul et al., 2012 Atorvastatin 6 months 56 Atorvastatin reduced PIIINP in heart failure patients.
CORONA Rosuvastatin 32.8 months 5,011 Rosuvastatin did not reduce the primary outcome or the number of deaths from
any cause in older patients with systolic heart failure.
GISSIF-HF Rosuvastatin 3.9 years 4,574 Rosuvastatin daily did not affect clinical outcomes in patients with chronic heart
failure of any cause.
UNIVERSAL Rosuvastatin 6 months 86 Rosuvastatin did not beneficially alter parameters of LV remodeling in patients
with chronic systolic heart failure.
TGF-β INHIBITORS
PRESTO Tranilast 1, or 3
months
11,484 Tranilast did not improve the quantitative measures of restenosis (angiographic
and intravascular ultrasound) or its clinical sequelae in patients receiving
successful percutaneous coronary intervention.
ENDOTHELIN INHIBITORS
Sütsch et al., 1998 Bosentan 2 weeks 36 Bosentan improved systemic and pulmonary hemodynamics in heart failure
patients who were symptomatic with standard triple-drug therapy.
EARTH Darusentan 24 weeks 642 Darusentan did not improve cardiac remodeling or clinical outcomes in patients
with chronic heart failure.
Prasad et al., 2006 Enrasentan 6 months 72 In asymptomatic patients with LV dysfunction, LVEDVI increased over 6 months
with enrasentan compared with enalapril treatment.
SELECTIVE HEART RATE-REDUCING DRUG
SHIFT Ivabradine 22.9 month
follow up
6,558 Ivabradine improved clinical outcomes in patients with symptomatic heart failure.
SHIFT substudy Ivabradine 8 month
follow up
411 Ivabradine reversed cardiac remodeling in patients with heart failure.
LOOP DIURETICS
López et al., 2004 Torsemide 8 months 36 Torsemide but not furosemide reduced PICP and CVF in hypertensive patients
with symptomatic heart failure.
López et al., 2007 Torsemide 8 months 22 Torsemide but not furosemide decreased PCP in patients with chronic heart
failure.
López et al., 2009 Torsemide 8 months 24 Torsemide corrected both lysyl oxidase overexpression and enhanced collagen
cross-linking leading to normalization of LV chamber stiffness in patients with
heart failure.
(Continued)
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TORAFIC Torsemide 8 months 155 In hypertensive patients with chronic heart failure randomized to torsemide or
furosemide, there were no difference in PICP levels between the two groups.
CYCLIC GMP-SPECIFIC PHOSPHODIESTERASE TYPE-5A INHIBITOR
Giannetta et al., 2012 Sildenafil 3 months 59 Sildenafil improved LV contraction parameters and reduced TGF-β and MCP-1 in
patients with diabetic cardiomyopathy.
Redfield et al., 2013 Sildenafil 24 weeks 216 Sildenafil did not improve exercise activity in patients with heart failure with
preserved ejection fraction.
MATRIX METALLOPROTEINASE INHIBITOR
PREMIER PG-116800 90 days 253 PG-11680 did not prevent LV remodeling or improve clinical outcomes 90 days
after myocardial infarction.
RELAXIN
Pre-RELAX-AHF Relaxin 48 h 234 Relaxin improved dyspnoea and lowered cardiovascular deaths or readmissions
due to heart or renal failure at day 60 in patients with acute heart failure.
RELAX-AHF Serelaxin 48 h 1,161 Serelaxin improved dyspnoea and reduced cardiovascular deaths and all-cause
mortality through day 180 in patients with acute heart failure.
CVF, collagen volume fraction; PICP, the carboxy-terminal peptide of procollagen type I; LV, left ventricular; PIIINP, the amino-terminal peptide of type III procollagen; PINP, the amino-
terminal peptide of type I procollagen (PINP); PCP, procollagen type I carboxy-terminal proteinase; TGF-β, transforming growth factor-β; MCP-1, monocyte chemoattractant protein-1;
LVEDVI, LV end diastolic volume index.
trials, the CORONA(Kjekshus et al., 2007) and GISSIF-HF
(Tavazzi et al., 2008) observed a neutral effect of rosuvastatin
compared to placebo on major clinical outcomes in heart failure.
Beneficial effects of statin on cardiac remodeling were not
observed in universal trial either (Krum et al., 2007). A sub-
study of universal trial actually showed reduced coenzyme-10
and increased serum collagen markers in the statin-treated group
(Ashton et al., 2011). So, statin’s effect on cardiac fibrosis in
human are generally disappointing. Peroxisome proliferator-
activated receptor (PPAR) agonists have anti-inflammation
properties. Preclinical data showed that PPAR-α agonist inhibited
cardiac fibrosis and improved cardiac function (Ogata et al.,
2004). However, considerable controversy exists on the cardiac
safety profile of PPAR agonists (Sarma, 2012). Overall, there
is lack of effective inflammatory modulators to inhibit cardiac
fibrosis in patients. However, the negative results of inflammatory
modulators do not necessarily mean the end of inflammatory
modulators in cardiac fibrosis. Future studies should identify
the crucial actors and their mechanisms of action in the
immunopathogenesis of cardiac fibrosis, which is a prerequisite
for the development of new inflammatory modulators in patients
with cardiac fibrosis. Selective p38 MAPK inhibitors blocking
the secretion of TNF-α and decreasing cardiac fibrosis in mice
(Westermann et al., 2006) may be a new treatment modality in
humans.
TGF-β inhibitors
TGF-β plays a central role in activating cardiac fibrosis
and it activates both canonical (ALK/Smad2/3/Smad4) and
noncanonical (TAK/p-38/JNK and NOX4/ROS) signaling
pathways. Anti-TGF-β antibodies and ALK5 inhibitors
attenuated cardiac fibrosis in animal models, but they were
associated with adverse cardiovascular effects (Frantz et al.,
2008; Engebretsen et al., 2014), suggesting that targeting
canonical TGF-β signaling pathway might not be applicable
clinically. While TGF-β promotes fibrogenesis, it also inhibits
inflammation, suggesting that broad targeting of TGF-β may be
problematic. Alternatively, targeting TAK or NOX4 downstream
of TGF-β might be viable anti-fibrotic approaches. Clinically,
two agents, pirfenidone and tranilast, which inhibit TGF-β
and other growth factors (Edgley et al., 2012), have been
available. Both pirfenidone and tranilast have been shown to
reduce cardiac fibrosis in animal studies (Edgley et al., 2012).
However, tranilast was disappointing in the PRESTO study for
post-percutaneous transluminal coronary angioplasty restenosis
prevention (Holmes et al., 2002). The use of pirfenidone and
tranilast also have adverse effects such as liver dysfunction.
Now research is being conducted to search for new compounds
that could overcome these potential safety concerns. A new
compound called FT011 displays improved activity and reduced
toxicity compared to tranilast (Zammit et al., 2009), which needs
to be investigated in clinical studies.
Endothelin Inhibitors
Endothelin is another important contributor of fibrotic process
and bosentan, a dual endothelin receptor subtype A and B
antagonist, prevents fibrosis of various organs in animal models
(Clozel and Salloukh, 2005). Dual endothelin subtype A and
B inhibitors bosentan and macitentan and the ETA inhibitor
ambrisentan are approved in the U.S. for the treatment of
pulmonary hypertension. An initial small study in human
showed that additional administration of bosentan improved
systemic and pulmonary hemodynamics in severe heart failure
patients receiving conventional treatments including ACE
inhibitors (Sütsch et al., 1998). However, most of subsequent
clinical trials of endothelin receptor antagonists were negative
or neutral (Anand et al., 2004; Prasad et al., 2006). The
harmful effects of endothelin receptor antagonists were generally
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attributable to enhanced fluid retention, which could be
alleviated by early diuretic therapy. However, in general,
additional blockade of endothelin may not be beneficial
in patients with heart failure or cardiac fibrosis receiving
angiotensin inhibitors.
β-Blockers
β-blockers have been demonstrated to prevent cardiac fibrosis
and improve survival in a rat model (Kobayashi et al., 2004).
A meta-analysis showed that the β-blockers treatment for the
patients with heart failure with preserved ejection fraction
was associated with a lower risk of all-cause mortality (Liu
et al., 2014). However, the mechanisms of β-blockers’ benefit
on mortality have not been precisely clarified and whether β-
blockers attenuate cardiac fibrosis in human remains unknown.
Selective Heart Rate-Reducing Treatment:
Ivabradine
Ivabradine is an oral medication that provides selective heart
rate reduction by inhibiting the f-channel. A large trial SHIFT
showed that over a median follow-up of 22.9 months, ivabradine
significantly reduced cardiovascular death or hospital admission
for worsening heart failure in patients with symptomatic heart
failure with an LV ejection fraction ≤35%, and in sinus
rhythm with a heart rate of ≥70 bpm (Swedberg et al., 2010).
An echocardiographic sub-study of SHIFT further found that
ivabradine improved both LV end-systolic and end-diastolic
volume indexes compared with placebo from baseline to the
8-month follow-up (Tardif et al., 2011). Thus, ivabradine has
been introduced in the treatment guidelines for chronic heart
failure in patients (McMurray et al., 2012). However, evidence
on whether ivabradine attenuates cardiac fibrosis in patients
with heart failure is still lacking although ivabradine effectively
reduced fibrosis and circulating angiotensin II and aldosterone
levels in animal models (Busseuil et al., 2010). Ivabradine could
also reduce fibrosis through its inhibitory effects on inflammatory
responses and cardiac apoptosis (Becher et al., 2012).
Loop Diuretics: Torsemide
There are three loop diuretics utilized in heart failure patients:
furosemide, torsemide, and bumetanide. López et al. reported
that torasemide (n = 19), but not furosemide (n = 17), reduced
circulating PICP and myocardial collagen in hypertensive
patients with symptomatic heart failure (López et al., 2004). They
then found that activation of the enzyme responsible for the
cleavage of PICP, procollagen type I carboxy-terminal proteinase
(PCP), was also decreased in 22 patients with chronic heart
failure taking torasemide (López et al., 2007). They further
reported the ability of torsemide to correct both lysyl oxidase
overexpression and enhanced collagen cross-linking leading to
normalization of LV chamber stiffness in patients with heart
failure (López et al., 2009). This was supported by preclinical
data showing torsemide’s effect on RAAS inhibition including
decreasing aldosterone secretion, inhibiting aldosterone receptor
and Ang II effects (Buggey et al., 2015). However, in the
TORAFIC study, a multi-center study of 155 hypertensive
patients with chronic heart failure randomized to torsemide
or furosemide, investigators did not find significant differences
between the two groups in changes of PICP (Group, 2011). The
TORAFIC study’s patient population had less severe heart failure
and lower baseline serum PICP compared to those in the studies
by Lopez and colleagues, which possibly explains the divergent
results among these studies. So, it is important to select patients
who may benefit from torsemide treatment.
Sildenafil
Sildenafil inhibits cyclic GMP-specific phosphodiesterase type-
5A and it has been used to treat idiopathic pulmonary fibrosis.
In the first proof-of-concept human study, 59 patients with
isolated diabetic cardiomyopathy randomly treated 3 months
with sildenafil showed improved LV contraction parameters
and reduced TGF-β and monocyte chemoattractant protein-1,
when compared with controls (Giannetta et al., 2012). However,
among patients with heart failure with preserved ejection fraction
sildenafil for 24 weeks (n = 113), compared with placebo (n =
103), did not improve exercise capacity or clinical status (Redfield
et al., 2013). Notably, fibrosis parameters were not measured in
these two studies. The discordant results indicate that the same
treatment does not exert similar effects in various cardiovascular
disease.
Matrix Metalloproteinase (MMP) Inhibitors
Cardiac fibrosis is associated with activation of MMPs. It has
been shown that MMP inhibition attenuates cardiac fibrosis and
LV remodeling in experimental models (Heymans et al., 2005;
Matsusaka et al., 2006). However, the PREMIER study of an orally
active MMP inhibitor, PG-116800, in 253 patients after M failed
to prevent LV remodeling or improve clinical outcomes 90 days
after MI (Hudson et al., 2006), although it should be noted that
no fibrosis parameters were measured in this study.
Relaxin
Relaxin is an intriguing endogenous hormone that is a potent
vasodilator with a number of pleiotropic effects. Relaxin inhibits
fibrosis through various mechanisms including inhibiting TGF-
β and Smad, regulating the balance between MMPs and tissue
inhibitors of metalloproteinases, and inhibiting inflammatory
response (Samuel et al., 2016). Relaxin has been shown to
have anti-fibrotic effects in a range of experimental models
of cardiovascular disease including MI (Samuel et al., 2011),
fibrotic cardiomyopathy (Samuel et al., 2014), hypertension
(Lekgabe et al., 2005), diabetes (Samuel et al., 2008), and
atrial fibrillation (Henry et al., 2016). Furthermore, relaxin
more effectively ameliorated cardiac fibrosis than enalapril in
an experimental model of fibrotic cardiomyopathy and relaxin
in combination with enalapril augmented the anti-fibrotic
efficacy of enalapril (Samuel et al., 2014). However, relaxin is
not universally beneficial in cardiac fibrosis since relaxin did
not affect pressure overload-induced cardiac fibrosis that was
associated with biochemical wall stress rather than elevated TGF-
β1 levels (Xu et al., 2008). The beneficial effects of a single 48-h
infusion of relaxin in the acute heart failure trials (Teerlink et al.,
2009, 2013) has led to great interest in its clinical application
in in human disease. Although anti-fibrotic effects of relaxin
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is well characterized in various experimental models, clinical
trials have failed in patients with other fibrotic conditions such
as scleroderma (Khanna et al., 2009). The negative results of
clinical trials of relaxin have pointed to the challenges previously
underscored. First, relaxin has short in vivo half-life and it
is costly to produce. The relatively short duration of relaxin
treatment have partly contributed to the failed clinical trials since
fibrosis is a slow process in human. Second, it is important
to know the expression of relaxin receptors in different tissues
and organs and to understand tissue competence to respond to
relaxin along with signaling pathways. Nevertheless, relaxin still
holds great potential as a therapy for cardiac fibrosis associated
with various cardiovascular disease.
CHALLENGES AND FUTURE DIRECTIONS
The failure of many clinical trials on anti-fibrotic drugs
indicates that extrapolating research data from animal models
to human requires caution since there are significant species
differences in physiology and genetics between animals and
human. Compared to mice, fibrosis is a slower condition in
humans, which takes decades to develop and require long-
term treatment to diminish its progression. Furthermore, many
animal models of diseases do not mimic various clinical settings,
thus controversial results are likely to be obtained since there
are different signaling pathways and mechanisms in cardiac
fibrotic processes in various diseases. In addition, the animals
used are normally young while patients with cardiac fibrosis
are at a more advanced age. In order to improve clinical
translation, it is important to design, conduct and analyse
animal experiments properly and to summarize data from animal
research adequately before conducting clinical trials. Moreover,
the failure of previous trials also emphasizes the need for optimal
design of future clinical trials including a selection of suitable
patients, appropriate dose, and route and timing and length of
administration.
There are some important areas for future research in this
field. First, although CMR is too expensive to be used in
large populations, it should be used to investigate potential
new treatments with relatively small group sizes since it allows
accurate assessment of regional and diffuse fibrosis. Second,
anti-fibrotic therapies targeting downstream signaling pathways
may improve safety and efficacy of current treatments such
as TGF-β inhibitors. In addition to their role in fibrosis,
many proteins are involved in other biological processes. Thus,
developing more specific agents targeting fibrotic signaling
pathways is likely to be beneficial to minimize potential
side effects. Third, combined anti-fibrotic therapies seem
more effective than single drug treatment. It is shown that
spironolactone or relaxin in combination with angiotensin II
inhibitors augmented anti-fibrotic efficacy (Kosmala et al., 2011;
Samuel et al., 2014). Combined anti-fibrotic agents with different
mechanisms of actions is likely to exert better effects on cardiac
fibrosis.
CONCLUSION
Although many fibrotic therapies on cardiac fibrosis are
promising in preclinical models, clinical translation is limited.
There is still a lack of effective treatments to regress cardiac
fibrosis in patients with various cardiovascular disease. Future
optimally designed clinical studies are required to test new
potential treatments and currently available drugs with improved
safety and efficacy after adequate analysis of evidence from
animal research.
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